Targets › UBA1
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology, Hematology; next expected readout Apr 2027.
Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system. Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP. Essential for the formation of radiation-induced foci, timely DNA repair…. (UniProt, P22314)
Open in Phaseline: the race on UBA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | TAK-243 Ubiquitin-activating enzyme (UAE) inhibitor | UBA1 | Phase 1 | Advanced Lymphoma; Myelodysplastic Syndrome With Excess Blasts | Apr 2027 |
| University of California, San Diego | SB-4826 Small ubiquitin-like modifier E1 inhibitor | UBA1 | Phase 1 | Non Hodgkin Lymphoma | Feb 2031 |
Advanced Lymphoma (1) Myelodysplastic Syndrome With Excess Blasts (1) Non Hodgkin Lymphoma (1)
small molecule (1), mixed (1)
National Cancer Institute (NCI) (1) University of California, San Diego (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.